This study was aimed to be conducted to determine the death anxiety and death-related depression of nurses who work in the Covid-19 intensive care units. The study was carried out descriptive study with 264 nurses working in 11 Covid-19 intensive care units within the pandemic department of a hospital. Data were collected by Nurse Introduction, Templer Death Anxiety Scale and Death Depression Scale. It was found that the anxiety levels of the nurses were high and their depression levels were moderate; The Death Anxiety Scale and Death Depression Scale scores of the nurses who did not feel any emotion related to the deaths of Covid patients were higher than those who felt sadness and anxiety (P<0.05). A moderate, positive and significant relationship was found between Death Depression Scale and Death Anxiety Scale total scale scores. For nurses working in intensive care, it is recommended to make new plans for crisis management and to take measures to manage death depression and anxiety.
Background:Since its inception, the COVID-19 outbreak has been carefully monitored both by the patients using DMARDs and their physicians. There is no data that patients with rheumatic and musculoskeletal diseases (RMD) are at a higher risk of contracting COVID-19 disease than those without RMD (1). COVID-19-related death in people with RMD has been associated with older age, male gender, concomitant cardiovascular and pulmonary diseases, moderate/high disease activity, and certain treatments (rituximab (RTX), sulfasalazine (SSZ) and some immunosuppressants) (2).Objectives:To determine the conditions of getting and being affected poorly by COVID-19 and related factors of RMD patients followed in our outpatient clinic.Methods:160 patients over 18 years of age who applied to our outpatient clinic between July 2020-January 2021; who used DMARDs for rheumatic diseases and agreed to participate were included in the study. The patients’s demographic data, RMDs, csDMARDs and b/tsDMARDs usage, comorbid diseases and smoking status were recorded. The data of the patients on COVID-19 disease between March 2020 and January 2021 were questioned at each visit.Results:Patient characteristics are presented in Table 1. 57 (36%) of all patients had COVID-19 PCR test, 23 (14%) were positive, and 1 patient was diagnosed with COVID-19 because the CT findings were positive, although the PCR test was negative.Table 1.Patient characteristicsAll Patients n=160COVID-19 Patients n=24Male61 (38%)6 (25%)Female99 (62%)18 (75%)Mean age49.549.5Ever smoker88 (55%)8 (33,3%)Obesity51 (32%)9 (37,5%)Hypertension (HT)46 (29%)7 (29%)Diabetes (DM)22 (14%)2 (8%)Cardiovascular disease (CVD)26 (16%)5 (20%)Chronic lung disease (CLD)12 (7,5%)4 (16%)SpA71 (44,3%)9 (37,5%)RA71 (44,3%)14 (58,3%)PsA14 (8,8%)1 (4,2%)SLE2 (1,25%)-PMR2 (1,25%)-cDMARD only82 (51,2%)14 (58,3%)b/tsDMARD only55 (34,4%)8 (33.3%)Combined DMARD23 (14,4%)2 (8.4%)The rate of getting COVID-19 infection was 15% in all patients. This rate was 18% in all obese patients, 19% in those with at least one comorbid disease (HT, DM, CVD, CLD), and 22% in those who were obese and had at least one comorbid disease. 16% of non-smokers and 9% of those who ever smoked got COVID-19. Among patients over the age of 65 (n=17), 2 patients (%12) had COVID-19. Treatments of RMDs of patients with COVID-19 were as follows: bDMARD=8 [(Etanercept(ETN) n=2, adalimumab (ADA) n=2, certolizumab pegol (CTZ) n=1, infliximab (IFX) n=1, golimumab (GOL) n=1, RTX n=1)], csDMARD=14 [(methotrexate (MTX) n=4, leflunomid (LEF) n=4, SSZ n=3, HCQ n=2, MTX+SSZ+HCQ n=1)], combined=2 [tofacitinib (TOF)+MTX n=1, TCZ+LEF n=1)], none of them was using glucocorticoids. Overall 17% of patients using csDMARD, 14,5% of patients using b/tsDMARD as monotherapy and 9% of patients using combination treatment had COVID-19. Of the patients using HCQ (n=14), 3 (21%) were diagnosed with COVID-19 disease. 18 of the patients received COVID-19 treatment at home, 6 were hospitalized and 1 of them (RA patient, LEF user) needed intensive care unit. None of them died.Conclusion:Preliminary results regarding the health status associated with COVID-19 of our patients with RMD are presented. Biologic drugs seems not to increase COVID-19 but final results will be presented after the completion of statistical analysis of all data.References:[1]Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851-858. doi:10.1136/annrheumdis-2020-217877[2]Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry [published online ahead of print, 2021 Jan 27]. Ann Rheum Dis. 2021;annrheumdis-2020-219498. doi:10.1136/annrheumdis-2020-219498Disclosure of Interests:None declared
BACKGROUND: The coronavirus disease (COVID-19) has greatly affected healthcare workers at the physical and psychosocial level. In this process, primary healthcare workers have taken the most active role by taking part in the filiation groups. OBJECTIVE: This study aimed to determine the anxiety and workload perception level of primary healthcare workers during the COVID-19 pandemic. METHODS: This was a cross-sectional study. An online survey was conducted among 197 healthcare workers. Personal Information Form, the Coronavirus Anxiety Scale and Work Overload Scale were used as data collection tools in the research. Independent Two-Sample T-Test, One-Way Analysis of Variance, Mann-Whitney U test and Kruskal Wallis test were used to evaluate the data. Moreover, the relationships between the scales were evaluated with Pearson correlation analysis and simple regression analysis. RESULTS: The median total score of the Coronavirus Anxiety Scale of healthcare workers was 3.0, and the mean score of the Work Overload Scale was 37.89±7.47. It was found that there was a correlation between the Coronavirus Anxiety and the Work Overload Scales and 21.0% of the variance changes in the Work Overload Scale were affected by coronavirus anxiety. CONCLUSION: It was determined that the level of coronavirus anxiety affects the perception of workload. Therefore, it is recommended that work plans should be made considering this situation.
Bu araştırma, Koronavirüs Salgını sürecinde birinci basamak sağlık çalışanlarının Covid-19 aşısına yönelik tutumlarını ve Covid-19 hastalık algıları arasındaki ilişkiyi belirlemek amacıyla tanımlayıcı-ilişkisel olarak yapılmıştır. Araştırmanın örneklemini Kayseri merkez ilçelerinde aile sağlığı merkezinde bulunan 63 sağlık çalışanı oluşturmaktadır. Çalışmada; Kişisel Bilgi Formu, Covid-19 Aşısına Yönelik Tutumlar Ölçeği ve Covid-19 Hastalık Algısı Ölçeği kullanılmıştır. Veriler online anketlerle toplanmıştır. Çalışmaya katılanların; %58.7'sinin aşının yan etkilerinden korkmadığı, %96.8'inin aşı olduğu, %95.2'sinin ailesindeki bireylerin aşı olduğu ve %95.2'sinin Covid-19 aşısını hastalarına önerdiği belirlenmiştir. Çalışmada, toplam puan median değerleri; aşıya yönelik olumlu tutumlar için: 4.5, aşıya yönelik olumsuz tutumlar için: 4.0, Covid-19 Hastalık Algısı tehlikelilik alt boyut için: 4.3, Covid-19 Hastalık Algısı bulaştırıcılık alt boyutu için 4.0 olarak saptanmıştır. Aşıya yönelik olumlu tutumlar ile tehlikelilik (rho=0.343, p=0.006) ve bulaştırıcılık (rho=0.342, p=0.006) alt boyutlarında ve aşıya yönelik olumsuz tutumlar ile tehlikelilik (rho=0.244, p=0.054) ve bulaştırıcılık (rho=0.369, p=0.003) alt boyutları arasında pozitif yönlü, zayıf ve anlamlı bir ilişki bulunmuştur (p<=0.05). Birinci basamak sağlık çalışanlarının Covid-19 aşısına yönelik olumlu tutumlarının olduğu, hastalıkla ilgili tehlikelilik algısının ve virüsün bulaştırıcılık algısının yüksek olduğu, ancak aralarındaki ilişkinin zayıf ve önemli olduğu bulunmuştur. Hastalık algısının gruplar üzerinde etkisi olduğu düşünülerek bu algının ve bu algıyla aşıya yönelik tutumların değiştirilmesi önerilmektedir.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.